Case Reports in Surgery

Case Reports in Surgery / 2014 / Article

Case Report | Open Access

Volume 2014 |Article ID 572805 | https://doi.org/10.1155/2014/572805

Emanuele Grasso, Fabio Marino, Michele Bottalico, Michele Simone, "A Case of Myxoid Liposarcoma of the Retroperitoneum: A Challenging Tumour for Diagnosis and Treatment", Case Reports in Surgery, vol. 2014, Article ID 572805, 4 pages, 2014. https://doi.org/10.1155/2014/572805

A Case of Myxoid Liposarcoma of the Retroperitoneum: A Challenging Tumour for Diagnosis and Treatment

Academic Editor: Mehrdad Nikfarjam
Received23 Jan 2014
Accepted20 May 2014
Published12 Jun 2014

Abstract

Retroperitoneal sarcomas are rare neoplasms that account for only 1%-2% of all solid tumors and liposarcomas represent the most frequent histological type. We describe the case of a 44-year-old female with a retroperitoneal myxoid liposarcoma of 22 × 19 × 8 cm in size. The only symptoms were persistent pain and progressive tenderness of the abdomen lasting for two months. The mass was radically excised during laparotomy. CT and MRI were useful to clarify the site of origin of the tumor, relationships with other organs, and planning surgery but final diagnosis was based on histological findings. Here we review the literature about the challenging diagnosis, treatment, and prognostic factors of this disease.

1. Introduction

Retroperitoneal sarcomas are rare tumors that account for only 1%-2% of all solid tumors. Most of sarcomas occur outside of the retroperitoneum and only 10%–20% of them originate in the retroperitoneal space. The overall incidence of retroperitoneal sarcomas is estimated at an average of 0.3%-0.4% for 100.000 inhabitants.

They are a group of heterogeneous neoplasms with many histological varieties; the most frequent histological types are liposarcomas (LS), leiomyosarcomas, and malignant fibrous histiocytomas. Liposarcoma is the most common soft tissue sarcoma, accounting for 20% of all sarcomas in adults.

The mortality rates for patients with LS range from 1% to 90%, and recurrence rates range from 5% to 83% depending on the histologic subtype and location [13]. Here we report a case of retroperitoneal LS and describe the histological characteristics and the difficulties in the diagnosis.

2. Case Report

A 44-year-old female was admitted to our hospital with persistent abdominal pain and a history of progressive tenderness of the abdomen becoming clinically evident during the last two months.

Physical examination showed a palpable mass especially extended in the right lower quadrant of the abdomen. Abdominal ultrasonography showed a solid, heterogeneous mass with multiple foci of variable size, probably starting from retroperitoneum, occupying most of abdominal and pelvic cavity and winding the distal 2/3 of right kidney (Figure 1).

Laboratory findings showed a moderate anaemia (haemoglobin level: 102 g/L).

Computed tomography (CT) of the abdomen and pelvis confirmed the presence of a 22 × 19 × 8 cm retroperitoneal mass, extending anteriorly to abdominal wall of right upper quadrant and winding the entire distal right kidney without findings of neoplastic infiltration. The tumor displaced the small bowel to the left and the right kidney to the anterior and pushed the uterus to the high quadrant of the abdomen. The mass was well defined from surrounding structures and showed heterogeneous attenuation (Figure 2). Other organs including liver, gallbladder, pancreas, and spleen were within the limit. Abdominal and pelvic magnetic resonance image (MRI) confirmed a retroperitoneal mass close to the right distal kidney.

At laparotomy, a huge mass was found and completely excised. The tumor showed adhesions to the uterus, urinary bladder, and right kidney, with displacement of the right colon, without infiltration of them. The mass was well encapsulated and multilobed with rubbery and gelatinous consistency and it weighed 1.1 kilograms (Figure 3).

Microscopically, the tumor consisted of round to polyhedral cells, which had round, often eccentric nuclei and abundant eosinophilic granular and microvacuolated cytoplasm, myxoid areas, suggesting a histological diagnosis of a retroperitoneal myxoid LS (Figure 4).

Postoperative course was uneventful and the patient was discharged on the 6th postoperative day.

Radiotherapy and chemotherapy using anthracycline-based therapy were given for 3 months.

After 2 years of clinical follow-up, the patient did not have evidence of disease recurrence.

3. Discussion

Retroperitoneal primitive neoplasms are rare accounting for only 0.3%–3% of all tumors. In most cases they are malignant tumors and in 75% of cases they are sarcomas. Liposarcoma is one of the most frequent soft tissue sarcomas found in adults. The main site of origin is the thigh (13–60%) while retroperitoneum is involved in 10–36% of cases [13].

The most common histologic subtype is myxoid LS (56.2%), followed by well-differentiated LS (21.9%), including dedifferentiated LS (6.8%), pleomorphic LS (17.8%), and round-cell LS (4.1%) [4].

In the English literature, the majority of patients (93%) had tumors of the well-differentiated/dedifferentiated subtypes. Dedifferentiated LS may be particularly difficult to recognize because they exhibit variable histologic findings but most frequently they resemble unclassified malignant fibrous histiocytoma-like pleomorphic sarcoma or intermediate- to high-grade myxofibrosarcoma [2].

Apart from different histology and malignancy, myxoid/round-cell LS and well-differentiated/dedifferentiated LS are different entities; in more than 95% of myxoid/round-cell LS, a classical t(12; 16) (q13; p11) or t(12; 22) (q13; q12) translocation can be found, which results in fusion of FUS-CHOP or EWSR1-CHOP gene, respectively. Characteristic genetic alteration for well-differentiated/dedifferentiated LS is the amplification of the 12q13–15 region, which includes MDM2 and CDK4 genes [5].

Although APC protein has been shown to be genetically or epigenetically inactivated in a variety of carcinomas, some authors have reported that they have not detected alterations of the APC gene in samples of myxoid/round-cell LS examined. However, they have demonstrated the presence of methylation of the APC promoter that induces a downregulation of the APC transcript [6].

Preoperatively, it is difficult to make definitive diagnosis of retroperitoneal LS because the MRI signal intensity of LS was heterogeneous and varied greatly, depending on the components of the tumour and the different histological patterns. Myxoid LS exhibited low signal intensity on T1W image and high signal intensity on T2W image. Well-differentiated LS presented in high signal intensity on T1W images, intermediate signal intensity on T2W images, and drop-out signal intensity on fat-suppressed MR images; round-cell LS and pleomorphic LS exhibited soft-tissue tumour signal intensity without characteristic of fat signal. Thus, MRI should be an ideal method to diagnose retroperitoneal LS [7].

The retroperitoneal tumors exhibit significant variability in symptoms and pain is the symptom most frequently complained about (60% of cases). Other clinical manifestations may be nausea, vomiting, bleeding, urinary retention, haematuria, dysuria, peripheral paralysis, thrombosis, edema of the lower limbs, weight loss, and fever [1, 4, 8].

Myxoid LS occurs predominantly in the extremities of young adults and has a disproportionately high tendency to metastasize to unusual soft tissue locations, before giving pulmonary metastasis or disseminated spread. Some authors have described cases of myxoid LS in the retropharyngeal space [9], in the right inguinal region presenting as painless inguinal mass [10], in the breast [11], and in the spermatic cord manifesting as painless scrotal or inguinal mass [12] and a primary localization in the pericardium [13]. Other sites of metastasis may be bones, thyroid gland [14], neck, small bowel [15], pericardium, and heart and in very rare cases myxoid LS may metastasize into the pancreas [16].

Jeng et al. report a rare case of retroperitoneal well-differentiated myxoid LS which occurred during pregnancy and was radically excised at the time of cesarean delivery at 36 weeks of gestation [17].

High-grade retroperitoneal sarcomas do significantly worse than low-grade tumors and up to 60% of patients with high-grade retroperitoneal sarcomas die of locally recurrent disease [18, 19]. The majority (78%) of myxoid LS patients developing bone metastases had a histologic high-grade primary tumor [20].

The treatment of myxoid LS needs a team of physicians including surgeons, oncologists, and radiotherapists.

Complete surgical excision is the mainstay of treatment for retroperitoneal sarcomas with emphasis to obtain negative microscopic margins [1822].

Hatano et al. describe that if a myxoid LS is adjacent to critical structures and wide resection cannot be performed, marginal or intralesional resection combined with postoperative radiotherapy (50–70 Gy, average 59.2 Gy) can achieve a high rate of local control [23]. There are no available results from prospective randomized trials comparing surgery versus surgery plus radiotherapy; however, in a recent review, the authors reported a 5-year local recurrence-free survival after surgery alone and surgery plus radiotherapy in the range of 23–54% and 40–62%, respectively. Furthermore, the respective 5-year rate of overall survival was of 33–49% and 48–64% [20].

The role of chemotherapy has not been well established but its application remains unsatisfactory due to low chemosensitivity of soft tissue sarcomas. Even the first line chemotherapeutic agent doxorubicin only yields a response rate of 18–29%. However, chemotherapy may improve local control and survival [22, 24].

The antibiotic salinomycin, a potassium ionophore, appears to increase the chemosensitivity of sarcoma cell lines to the doxorubicin; therefore, it may be used to decrease the doxorubicin dosage and its toxic side effects [25]. Finally, some authors have published a treatment with Nutlin-3a, an antagonist of MDM2 that stabilized p53 and induced downstream p53 dependent transcription, apoptosis, and growth arrest in LS subtypes cells which overexpress MDM2. Thus, Nutlin represents a promising new therapeutic principle for the treatment of selective groups of sarcomas [26, 27].

The tumor size affects prognoses of patients with intra-abdominal or retroperitoneal liposarcoma; prognoses of patients with large tumors (>20 cm) appear to be significantly poorer than those of patients with small tumors (<20 cm) [28]. Furthermore, vascular involvement seems to be associated with a decreased survival rate [29].

4. Conclusion

Our case confirms that retroperitoneal myxoid LS is a challenging tumor for diagnosis and treatment. CT and MRI are essential for assessing the retroperitoneal origin of the tumor, its spread, and planning surgery but final diagnosis was based on histological findings. The overall 5-year survival rate for these neoplasms remains low and surgery appears to be the only option for effective treatment. Chemo- and radiation therapy may improve local control and survival. Tumor size, histologic subtype, grade of tumors, and vascular involvement are important prognostic factors.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Emanuele Grasso and Fabio Marino contributed equally to this work.

References

  1. P. C. McGrath, “Retroperitoneal sarcomas,” Seminars in Surgical Oncology, vol. 10, no. 5, pp. 364–368, 1994. View at: Publisher Site | Google Scholar
  2. C. Mettlin, R. Priore, U. Rao, D. Gamble, W. Lane, and P. Murphy, “Results of the national soft-tissue sarcoma registry,” Journal of Surgical Oncology, vol. 19, no. 4, pp. 224–227, 1982. View at: Publisher Site | Google Scholar
  3. K. M. Dalal, M. W. Kattan, C. R. Antonescu, M. F. Brennan, and S. Singer, “Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk,” Annals of Surgery, vol. 244, no. 3, pp. 381–389, 2006. View at: Publisher Site | Google Scholar
  4. D. Nemanqani, W. A. Mourad, M. Akhtar et al., “Liposarcoma: a clinicopathological study of 73 cases diagnosed at King Faisal Specialist Hospital and Research Centre,” Annals of Saudi Medicine, vol. 19, no. 4, pp. 299–303, 1999. View at: Google Scholar
  5. R. S. A. De Vreeze, D. De Jong, I. H. G. Tielen et al., “Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis,” Modern Pathology, vol. 22, no. 2, pp. 223–231, 2009. View at: Publisher Site | Google Scholar
  6. S. Sievers, C. Fritzsch, M. Lehnhardt et al., “Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma,” International Journal of Cancer, vol. 119, no. 10, pp. 2347–2352, 2006. View at: Publisher Site | Google Scholar
  7. T. Song, J. Shen, B. L. Liang, W. W. Mai, Y. Li, and H. C. Guo, “Retrperitoneum Liposarcoma: MR characteristics and pathological correlative analysis,” Abdominal Imaging, vol. 32, no. 5, pp. 668–674, 2007. View at: Publisher Site | Google Scholar
  8. S. Y. Lee, B. K. P. Goh, M. C. C. Teo et al., “Retroperitoneal liposarcomas: the experience of a tertiary Asian center,” World Journal of Surgical Oncology, vol. 9, article 12, 2011. View at: Publisher Site | Google Scholar
  9. J.-G. He, H. Jiang, B.-B. Yang, and P.-F. Lin, “Liposarcoma of the retropharyngeal space with rapidly worsening dyspnea: a case report and review of the literature,” Oncology Letters, vol. 5, no. 6, pp. 1939–1942, 2013. View at: Publisher Site | Google Scholar
  10. K. Yoshida, E. Nakamura, T. Kawahara et al., “A case of myxoid liposarcoma in the right inguinal region: a case report,” Acta Urologica Japonica, vol. 52, no. 9, pp. 727–731, 2006. View at: Google Scholar
  11. T. Saito, M. Ryu, Y. Fukumura et al., “A case of myxoid liposarcoma of the breast,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 7, pp. 1432–1436, 2013. View at: Google Scholar
  12. A. Panagis, G. Karydas, J. E. Vasilakakis, E. Chatzipaschalis, M. Lambropoulou, and N. Papadopoulos, “Myxoid liposarcoma of the spermatic cord: a case report and review of the literature,” International Urology and Nephrology, vol. 35, no. 3, pp. 369–372, 2003. View at: Publisher Site | Google Scholar
  13. M.-F. Gan, H.-S. Lu, S.-X. Weng, J.-F. Cai, and W.-G. Bao, “Primary myxoid liposarcoma of the pericardium,” Chinese Journal of Pathology, vol. 35, no. 3, pp. 185–186, 2006. View at: Google Scholar
  14. J. R. Tysome, A. Sandison, and P. M. Clarke, “Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review,” Journal of Laryngology and Otology, vol. 120, no. 6, pp. 511–513, 2006. View at: Publisher Site | Google Scholar
  15. A. Monjazeb, C. Stanton, and E. A. Levine, “Intussusception secondary to metastasis from a low-grade retroperitoneal liposarcoma,” American Surgeon, vol. 70, no. 9, pp. 775–778, 2004. View at: Google Scholar
  16. F. Carboni, G. M. Ettorre, R. Lorusso et al., “Isolated pancreatic metastasis of extremity myxoid liposarcoma: report of a case,” Japanese Journal of Clinical Oncology, vol. 36, no. 10, pp. 662–664, 2006. View at: Publisher Site | Google Scholar
  17. C.-J. Jeng, C.-Y. Tzen, W.-C. Huang, Y.-C. Yang, J. Shen, and C.-R. Tzeng, “Recurrent retroperitoneal myxoid liposarcoma during pregnancy: a case report and literature review,” International Journal of Gynecological Cancer, vol. 15, no. 6, pp. 1235–1238, 2005. View at: Publisher Site | Google Scholar
  18. J. J. Lewis, D. Leung, J. M. Woodruff, and M. F. Brennan, “Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution,” Annals of Surgery, vol. 228, no. 3, pp. 355–365, 1998. View at: Publisher Site | Google Scholar
  19. T. R. Donahue, M. W. Kattan, S. D. Nelson, W. D. Tap, F. R. Eilber, and F. C. Eilber, “Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram,” Cancer, vol. 116, no. 16, pp. 3883–3891, 2010. View at: Publisher Site | Google Scholar
  20. P. Agoston, J. Kliton, Z. Mátrai, and C. Polgár, “Role of radiotherapy in the treatment of retroperitoneal soft tissue sarcomas,” Magyar Onkológia, vol. 58, no. 1, pp. 77–82, 2014. View at: Google Scholar
  21. J. H. Schwab, P. Boland, T. Guo et al., “Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread,” Annals of Surgical Oncology, vol. 14, no. 4, pp. 1507–1514, 2007. View at: Publisher Site | Google Scholar
  22. F. Pacelli, A. P. Tortorelli, F. Rosa et al., “Retroperitoneal soft tissue sarcoma: prognostic factors and therapeutic approaches,” Tumori, vol. 94, no. 4, pp. 497–504, 2008. View at: Google Scholar
  23. H. Hatano, A. Ogose, T. Hotta et al., “Treatment of myxoid liposarcoma by marginal or intralesional resection combined with radiotherapy,” Anticancer Research, vol. 23, no. 3, pp. 3045–3049, 2003. View at: Google Scholar
  24. J. E. Mullinax, J. S. Zager, and R. J. Gonzalez, “Current diagnosis and management of retroperitoneal sarcoma,” Cancer Control, vol. 18, no. 3, pp. 177–187, 2011. View at: Google Scholar
  25. S. T. Liffers, D. J. Tilkorn, I. Stricker et al., “Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas,” BMC Cancer, vol. 13, article 490, 2013. View at: Google Scholar
  26. H. O. Ohnstad, R. Castro, J. Sun et al., “Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma,” Cancer, vol. 119, no. 5, pp. 1013–1022, 2013. View at: Publisher Site | Google Scholar
  27. A. M. Lazar, E. Brǎtucu, N. D. Straja et al., “Primitive retroperitoneal tumors. Vascular involvement—a major prognostic factor,” Chirurgia, vol. 107, no. 2, pp. 186–194, 2012. View at: Google Scholar
  28. T. Sato, G. Nishimura, A. Nonomurat, and K. Miwa, “Intra-abdominal and retroperitoneal liposarcomas,” International Surgery, vol. 84, no. 2, pp. 163–167, 1999. View at: Google Scholar
  29. C. R. Müller, E. B. Paulsen, P. Noordhuis, F. Pedeutour, G. Sæter, and O. Myklebost, “Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A,” International Journal of Cancer, vol. 121, no. 1, pp. 199–205, 2007. View at: Publisher Site | Google Scholar

Copyright © 2014 Emanuele Grasso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views3310
Downloads561
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.